Skip to content

Neurophysiological and Behavioral Study of the Cognitive Deficits Associated With Cerebral Small Vessel Disease in the SHIVA Cohort. SHIVA-CogNeurophys

Neurophysiological and Behavioral Study of the Cognitive Deficits Associated With Cerebral Small Vessel Disease in the SHIVA Cohort - SHIVA-CogNeurophys

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07068620
Acronym
SHIVA-CogNeuro
Enrollment
80
Registered
2025-07-16
Start date
2025-08-07
Completion date
2028-03-07
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Small Vessel Disease, Cognitive Complaint, Stroke

Keywords

Cognitive decline, dementia, stroke, small vessel disease, healthy brain aging, electroencephalography, neuromodulation, transcranial alternating current stimulation, cognitive training, cognitive rehabilitation

Brief summary

Cerebral small vessel disease (cSVD) is characterized by an alteration of the structure and function of small penetrating brain arteries. Highly prevalent in older individuals from the general population, it represents a leading cause of stroke and a major contributor to cognitive decline and risk of dementia. Better detection and management of covert cSVD would have a major impact on preventing disability and costs related to stroke, cognitive impairment and dementia. The aim of the present study is to identify novel electroencephalographic (EEG) biomarkers of the cognitive deficits associated with cSVD, and how these biomarkers and cognitive performance are affected by personalized cognitive training or transcranial alternating current stimulation (tACS), a non-invasvie brain stimulation technique.

Detailed description

cSVD is by far the most prevalent vascular contributor to cognitive impairment in the population. However, accurate quantitative estimates of the predictive ability of cSVD for risk of dementia are lacking. Moreover, stratification of cognitive decline and risk of dementia in cSVD patients according to imaging characteristics as well as evidence of coexisting neurodegenerative disease and vascular comorbidity are lacking. Moreover, there is currently no specific mechanism-based treatment, leading to empirical and heterogeneous clinical practice, which in most instances consists of ignoring these lesions. This clinical blind spot represents a major "missed opportunity" for the prevention of cognitive decline and dementia. This study aims to explore the electroencephalographic (EEG) characteristics of patients with either extensive or minimal neurovascular lesions due to cSVD in 80 patients above 60 years old. The main goal is to identify EEG biomarkers that characterize these lesions and the associated cognitive deficits. Secondary objectives aim to assess the potential impact of cognitive training paradigms and non-invasive brain stimulation (namely transcranial alternating current stimulation - tACS) on these biomarkers and on cognitive performance. Participants will be divided into two groups. The first group will consist of patients with no or minor white matter hyperintensities on brain MRI (i.e. features of minor cSVD) , while the second group will include patients with moderate to severe white matter hyperintensities (i.e., features of extensive cSVD). This exploratory study leverages the uniqueness of the SHIVA cohort, a deeply characterized resource for investigation of cSVD. To our knowledge, the combination of EEG recordings, cognitive training, and noninvasive brain stimulation in cSVD patients is entirely novel

Interventions

DEVICEHome-based cognitive training

All interventions will be carried out for both groups of participants, with either minimal or extensive cSVD. Upon enrollment, each participant will undergo two hospital visits (visit 1 at day 0, visit 2 at day 7), followed by a home-based cognitive training across 10 days (days 15-24), two more hospital visits (visit 3 at day 26, visit 4 at day 33), and finally a follow-up cognitive testing at home after 6 months.

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients included or previously included in the SHIVA cohort * Basic computer skills (ability to open a browser, use a mouse and keyboard) * Access to a personal computer with an internet connection * Independent in Activities of Daily Living (ADL) with a score ≥ 5/6, and in Instrumental Activities of Daily Living (IADL) with a score ≥ 4/8 * Informed and written consent signed by the participant and the investigating physician for this study

Exclusion criteria

* Motor impairments preventing the use of a keyboard and mouse (e.g., motor issues related to severe hand osteoarthritis) * Depressive symptoms indicated by a score of 2 to 4 on the mini Geriatric Depression Scale (mini GDS), which includes 4 items * Age-related macular degeneration (AMD) * Untreated glaucoma * Untreated psychiatric conditions that interfere with cognitive assessments * Diagnosed attention deficit disorder with or without hyperactivity or patients who could not complete all cognitive tests required in the SHIVA cohort * Systemic diseases that cause cognitive changes, such as obesity and metabolic disorders * History of epilepsy or seizures * Scalp sensitivity or skin lesions (dermatitis, wounds, etc.) Contraindications for the use of electrical stimulation: * Surgical clips, metal sutures, staples, stents * Osteosynthesis material in the head or neck * Pacemaker * Implanted hearing aid * Ocular foreign bodies, shrapnel, bullets * Metalworker * Pacemaker or neurostimulator * Heart valve or endovascular material * Ventricular shunt valve * Recent exposure (\< 6 months) to brain stimulation (tDCS, TMS, etc.) * Ongoing participation in a clinical trial or cognitive training program

Design outcomes

Primary

MeasureTime frameDescription
EEG signal powerDay 0, Day 26, Day 33The primary outcome measure is the average EEG signal power (across different frequency bands and for various electrodes) between the two participant groups with either minor or extensive cSVD

Countries

France

Contacts

CONTACTIGOR SIBON, MD, PhD
igor.sibon@chu-bordeaux.fr0556795313

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026